Published in Rev Port Cardiol on November 01, 2004
Induction of IL-6 expression by mechanical stress in the trabecular meshwork. Biochem Biophys Res Commun (2005) 1.06
Is the OSCE a feasible tool to assess competencies in undergraduate medical education? Med Teach (2013) 1.52
The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port (2014) 1.42
Incidence and prevalence of hypercholesterolemia in Portugal: a systemic review. Part II. Rev Port Cardiol (2003) 1.38
Novel FOXF1 mutations in sporadic and familial cases of alveolar capillary dysplasia with misaligned pulmonary veins imply a role for its DNA binding domain. Hum Mutat (2013) 1.23
Nonoptical massive parallel DNA sequencing of BRCA1 and BRCA2 genes in a diagnostic setting. Hum Mutat (2013) 1.12
Human spermatogenic failure purges deleterious mutation load from the autosomes and both sex chromosomes, including the gene DMRT1. PLoS Genet (2013) 1.08
Intention-to-treat analysis in clinical trials: principles and practical importance. Rev Port Cardiol (2002) 0.99
A novel mutation in FOXF1 gene associated with alveolar capillary dysplasia with misalignment of pulmonary veins, intestinal malrotation and annular pancreas. Neonatology (2013) 0.96
Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part I. Rev Port Cardiol (2003) 0.96
Gene expression pattern of IGF2, PHLDA2, PEG10 and CDKN1C imprinted genes in spontaneous miscarriages or fetal deaths. Epigenetics (2010) 0.94
Unique t(Y;1)(q12;q12) reciprocal translocation with loss of the heterochromatic region of chromosome 1 in a male with azoospermia due to meiotic arrest: a case report. Hum Reprod (2005) 0.91
Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part III. Rev Port Cardiol (2003) 0.90
Polymorphic DAZ gene family in polymorphic structure of AZFc locus: Artwork or functional for human spermatogenesis? APMIS (2003) 0.89
Characterization of cystic fibrosis conductance transmembrane regulator gene mutations and IVS8 poly(T) variants in Portuguese patients with congenital absence of the vas deferens. Hum Reprod (2004) 0.81
Cytological and expression studies and quantitative analysis of the temporal and stage-specific effects of follicle-stimulating hormone and testosterone during cocultures of the normal human seminiferous epithelium. Biol Reprod (2008) 0.80
Identification of new breakpoints in AZFb and AZFc. Mol Hum Reprod (2008) 0.80
DAZ gene copies: evidence of Y chromosome evolution. Mol Hum Reprod (2006) 0.79
A novel splicing mutation causes analbuminemia in a Portuguese boy. Mol Genet Metab (2011) 0.79
AZFb microdeletions and oligozoospermia--which mechanisms? Fertil Steril (2012) 0.78
Diagnostic testing, pre- and post-test probabilities, and their use in clinical practice. Rev Port Cardiol (2004) 0.77
A novel missense mutation P1290S at exon-20 of the CFTR gene in a Portuguese patient with congenital bilateral absence of the vas deferens. Fertil Steril (2005) 0.77
[Alopecia areata: a retrospective study of the paediatric dermatology department (2000-2008)]. Acta Med Port (2011) 0.76
Expression analysis of MLH3, MLH1, and MSH4 in maturation arrest. Reprod Sci (2012) 0.76
Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors. Rev Port Cardiol (2008) 0.75
Studies of harm. Clinical applications. Rev Port Cardiol (2005) 0.75
Calculation, expression and perception of risk in medicine: implications for clinical decision-making. Rev Port Cardiol (2011) 0.75
[Guidelines: unity and balance]. Rev Assoc Med Bras (2009) 0.75
Prevention and screening. Part I: General principles. Rev Port Cardiol (2002) 0.75
Types of clinical studies. II. Cohort studies. Rev Port Cardiol (2005) 0.75
Costs of illness due to hypeercholesterolemia in Portugal. Rev Port Cardiol (2004) 0.75
[Liaison psychiatry in a general hospital: seven paradigmatic cases]. Acta Med Port (2009) 0.75
Prevalence of hypercholesterolemia in Portugal and Europe: the same reality? Rev Port Cardiol (2003) 0.75
Prevention and screening. Part II: Critical appraisal of articles on screening. Rev Port Cardiol (2003) 0.75
Drug therapy for chronic heart failure due to left ventricular systolic dysfunction. II. Diuretics. Rev Port Cardiol (2008) 0.75
Drug class effects: definitions and practical applications. Rev Port Cardiol (2002) 0.75
Basics of methodologic analysis of therapeutic trials. Part II: Importance of the results. Rev Port Cardiol (2002) 0.75
Asymptomatic carotid bruit. Rev Port Cardiol (2005) 0.75
Randomization methods in clinical trials. Rev Port Cardiol (2004) 0.75
[Off-label prescribing: scientific analysis taking the use of bevacizumab in ophthalmology as an example]. Acta Med Port (2013) 0.75
Burden of disease from hypercholesterolemia in Portugal. Rev Port Cardiol (2004) 0.75
Basics of methodologic analysis of therapeutic trials. Part I: Validity of the results. Rev Port Cardiol (2002) 0.75
Types of clinical studies. Systematic reviews. Rev Port Cardiol (2006) 0.75
[Inflammatory myopathy with an unusual evolution]. Acta Reumatol Port (2010) 0.75
Basics of methodologic analysis of therapeutic trials. Part III: applicability of the results to the individual patient. Rev Port Cardiol (2002) 0.75
Types of clinical studies. IV. Clinical trials. Rev Port Cardiol (2005) 0.75
The therapeutic approach to paroxysmal or persistent atrial fibrillation: rhythm control versus rate control. A review. Rev Port Cardiol (2004) 0.75
[Smoking cessation: evidence-based recommendations]. Rev Port Cardiol (2002) 0.75